Clinical Trials

All Clinical Trials

(xIRB) DRUG BDTX-1535-101: A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial. Who Can Participate? Eligibility Criteria Some of the eligibility criteria include: · Participants must have a diagnosis of Glioblastoma or Non-Small Cell Lung Cancer · Participants must be 18 or older Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial. Principal Investigator, Study ID, Keywords Principal Investigator Patel, Jyoti D ClinicalTrials.gov IdentifierNCT05256290 IRB number STU00218568

(xIRB) DRUG BDTX-1535-101: A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer

This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care

Note: This is only a partial description of the study. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University if you are interested in the trial.

Who Can Participate?

Eligibility Criteria

Some of the eligibility criteria include:

· Participants must have a diagnosis of Glioblastoma or Non-Small Cell Lung Cancer

· Participants must be 18 or older

Note: This is only a partial list of eligibility criteria. Please contact the Robert H. Lurie Comprehensive Cancer Center of Northwestern University for complete screening information if you are interested in this clinical trial.

Principal Investigator, Study ID, Keywords

Principal Investigator

Patel, Jyoti D

ClinicalTrials.gov IdentifierNCT05256290

IRB number STU00218568